PS129 Alpha-Synuclein Detection via Antibody Segmentation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for detecting alpha-synuclein phosphorylated at serine 129 (PS129 alpha-synuclein) lack sufficient sensitivity and specificity, particularly in diagnosing and monitoring synucleinopathic diseases such as Parkinson's disease, where PS129 alpha-synuclein levels are often low and difficult to distinguish from total alpha-synuclein.
Innovation Solution
A method involving a capture antibody that preferentially binds to PS129 alpha-synuclein and a reporter antibody that binds to an epitope within residues 40-55 of alpha-synuclein, forming a sandwich complex, which is then detected to indicate the presence or absence of PS129 alpha-synuclein, using antibodies like 11A5 and 23E8, optionally with fluorescent labeling and magnetic beads for enhanced sensitivity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If conventional detection methods are used for alpha-synuclein, then the detection process is simple, but the sensitivity and specificity are insufficient to distinguish PS129 alpha-synuclein from total alpha-synuclein
Solution Approach 1:
The detection method is segmented into two distinct antibody binding events: first, a capture antibody binds to PS129 alpha-synuclein, then a reporter antibody binds to a different epitope on the same target. This segmentation allows specific detection of phosphorylated alpha-synuclein while distinguishing it from total alpha-synuclein, thereby improving measurement precision without requiring overly complex equipment
Solution Approach 2:
The capture antibody serves as an intermediary that selectively binds to PS129 alpha-synuclein, enabling the reporter antibody to then bind and produce a detectable signal. This intermediary mechanism provides high specificity for detecting phosphorylated alpha-synuclein in complex biological samples, resolving the contradiction between detection precision and method complexity
2Reliability
If total alpha-synuclein levels are measured, then the measurement is straightforward, but the levels show substantial overlap between subjects with and without disease
Solution Approach 1:
Instead of measuring total alpha-synuclein uniformly, the method targets the specific local modification of phosphorylation at serine 129. The capture antibody is designed to recognize this specific post-translational modification, providing diagnostic reliability by detecting the pathological form of alpha-synuclein that distinguishes synucleinopathic disease from normal conditions
Solution Approach 2:
The method changes the detection parameter from total alpha-synuclein concentration to phosphorylated alpha-synuclein (PS129) levels. This parameter change increases diagnostic reliability because PS129 levels are specifically elevated in synucleinopathic diseases, whereas total alpha-synuclein levels show substantial overlap between diseased and healthy subjects
3Measurement precision
If a sandwich complex assay is used to detect PS129 alpha-synuclein, then the sensitivity increases to low picomolar levels, but the assay procedure becomes more complex
Solution Approach 1:
The capture antibody is pre-immobilized on magnetic beads before sample addition. This preliminary action simplifies the overall assay operation by eliminating the need for complex sample preparation and enabling straightforward magnetic separation of bound complexes, while maintaining the high sensitivity of the sandwich assay format
Solution Approach 2:
Magnetic beads replace traditional solid-phase supports in the sandwich assay. This substitution simplifies the assay operation by enabling easy separation and washing of bound complexes through magnetic fields, improving ease of operation while maintaining the high measurement precision of the sandwich complex format
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach provides high sensitivity for detecting PS129 alpha-synuclein at low picomolar levels, enabling accurate diagnosis and monitoring of synucleinopathic diseases by differentiating phosphorylated alpha-synuclein from total alpha-synuclein, thereby aiding in disease progression and treatment assessment.
Implementation Method 1
contacting a sample with a capture antibody that preferentially binds to PS129 alpha-synuclein and a reporter antibody that specifically binds to an epitope within residues 40-55 of alpha-synuclein; wherein if PS129 alpha-synuclein is present in the sample, the capture antibody and reporter antibody bind to the PS129 alpha-synuclein forming a sandwich complex
Implementation Method 2
the capture antibody is attached to magnetic beads, which are separated from the remainder of the sample or resuspended solution by applying a magnetic field
Implementation Method 3
the reporter antibody is fluorescently labeled, and is detected by single-molecule counting
Data Source
AI summary
The invention provides methods of detecting alpha-synuclein using a capture antibody and a reporter antibody. The capture antibody binds preferentially to full-length alpha-synuclein phosphorylated at residue 129 (PS129 alpha-synuclein) over unphosphorylated full-length alpha-synuclein. The 11A5 antibody is an example of a suitable capture antibody. The reporter antibody binds to an epitope within residues 40-55 of alpha-synuclein. The 23E8 antibody is an example of such an antibody. Because only a small proportion of alpha-synuclein is phosphorylated high sensitivity of detection below picomolar is advantageous.